Dr. Jack Puymirat M.D., Ph.D., is a neurologist, clinician-scientist at the CHU Research Centre of Quebec, and professor in the Department of Medicine at Laval University. His work focuses on the study of neuromuscular diseases, headaches, as well as the development of a platform for the production of induced pluripotent human stem cells. Recently, his work on stem cell production was featured on Radio-Canada’s Découverte program. He has received several nominations, including the 2006 Researcher of the Year Award from Muscular Dystrophy Canada and the 2011 Hans Steinert Award from international myotonic dystrophy (Steinert’s disease) consortium.
Research on neuromuscular diseases
Steinert myotonic dystrophy is a muscular dystrophy that is 20 times more prevalent in the Saguenay-Lac-Saint-Jean region than anywhere else in the world. In 2000, it was established that the disease was due to the accumulation of mutated RNAs in the cell nucleus. Dr. Puymirat’s research has focused on the development of gene therapy, based on the destruction of toxic RNAs by antisense oligonucleotides. In 2016, his work led to the first Phase 1 clinical trial in the United States. In parallel with his research, Dr. Puymirat and his team have a clinical research program focusing on: 1) The establishment of a provincial registry for this disease to facilitate research and patient participation in clinical trials. 2) The development and validation of protocols for the quantification of muscle strength, the study of muscle imaging and the search for biomarkers of the disease for future clinical trials. 3) The development of genetic tests for various neuromuscular diseases, tests which are now used clinically and offered to the population of Quebec.
The induced pluripotent stem cells production platform (iPSC)
Thanks to the financial support of Brain Canada, Dr. Puymirat and his team have developed a platform for the production of induced pluripotent human stem cells. These cells can be derived from skin, blood, urine and immortalized lymphoblastic cell lines. These cells can differentiate into various cell types, particularly neurons, muscle cells and heart cells. They are used to model neurodegenerative, neuromuscular and psychiatric diseases, screen drugs, and develop cell therapies.
Pharmacogenomics in migraine
This research aims to identify blood molecular markers that are predictive of the response to different drugs used in the treatment of migraine. As a first step, Dr. Puymirat and his team are developing a migraine patient registry, which is essential for genomics studies. This registry contains information on the response to different drugs and will be extended to the CHUM as well as the Montreal Neurological Institute.
Local R-211, LOEX/ CMDGT
Québec, Québec,, Québec
Canada G1J 1Z4
Data not available
- De Serres-Bérard, ThiéryEmployeeHôpital de l'Enfant-Jésus+1 418-525-4444, extension firstname.lastname@example.org
1401 18 ième Rue
Canada G1J 1Z4
- Racine, VéroniqueEmployeeHôpital de l'Enfant-Jésus+1 418-990-8255, extension 61679+1 418-990-8248Veronique.Racine@crchudequebec.ulaval.ca
1401, 18e Rue
Canada G1J 1Z4
Ankle Strength Impairments in Myotonic Dystrophy Type 1: A Five-Year Follow-up.Journal Article
J Neuromuscul Dis, 2018, ISSN: 2214-3599.
rbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences.Journal Article
Nat Commun, 9 (1), pp. 2009, 2018, ISSN: 2041-1723.
Correction of GSK3β at young age prevents muscle pathology in mice with myotonic dystrophy type 1.Journal Article
FASEB J, 32 (4), pp. 2073-2085, 2018, ISSN: 0892-6638.
Lymphoblastoids cell lines - Derived iPSC line from a 26-year-old myotonic dystrophy type 1 patient carrying (CTG)200 expansion in the DMPK gene: CHUQi001-A.Journal Article
Stem Cell Res, 26 , pp. 103-106, 2018, ISSN: 1873-5061.
Implication of SPARC in the modulation of the extracellular matrix and mitochondrial function in muscle cells.Journal Article
PLoS ONE, 13 (2), pp. e0192714, 2018.
- Centre de recherche en organogenèse expérimentale, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 2011-05-01 to 2020-09-22
- Centre hospitalier universitaire de Québec - CHU de Québec-Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
- Centre thématique de recherche en neurosciences, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1999-06-01 to 2020-10-18
- Phase I/II clinical trial of myoblast transplantation to Duchenne Muscular Dystrophy patients., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2013-10-01 to 2020-03-31
- Roles of exercise-induced gene, SPARC, against sarcopenia: Link between extracellular matrix and mitochondria., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2014-04-01 to 2019-03-31
Recently finished projects
- Elimination of toxic RNA in myotonic dystrophy brain., Subvention, Muscular Dystrophy Association (USA), Subvention de recherche, from 2016-08-01 to 2017-03-31
- Evaluation of peptide antisense oligonucleotides as gene therapy for myotonic dystrophy., Subvention, Association française contre les myopathies, from 2013-09-01 to 2016-06-30
- Human inducible pluripotent stem cells (IPSC) plateform, Subvention, La Fondation Neuro Canada / Brain Canada, Soutien aux plateformes technologiques (SSPT), from 2015-04-01 to 2018-03-31
- Réseau de médecine génétique appliquée: Epidémiologie génétique (axe 5), Subvention, Fonds de recherche du Québec - Santé, Réseaux thématiques de recherche, from 2000-07-01 to 2017-06-30